Abstract:Herein, we report the design and synthesis of a novel series of 6-((1 H -1,2,3-triazol-4-yl)methyl)-6 H -indolo[2,3- b ]quinoxalines ( 22–29 ) via the copper( I )-catalyzed azide–alkyne cycloaddition (CuAAC) reaction. The target compounds formed through two pathways (A and B). The structures of the newly click synthesised 1,2,3-triazole-6 H -indolo[2,3- b ]quinoxalines ( 22–29 ) were confirmed on the basis of their elemental analysis and spectral data. Some of these compounds exhibited significant antiproliferative effects against tested cancer cells, including hepatocellular carcinoma (Hep-G2), breast cancer (MCF-7), and colon cancer (HCT116), relative to healthy noncancerous control skin fibroblast cells (BJ-1) to evaluate their cytotoxic effects. Among the tested compounds, compound 27 exhibited strong activity with IC 50 = 9.3 ± 1.1, 1.5 ± 0.1, 2.4 ± 0.2, and 17.3 ± 1.2 against cancer cell lines HCT-116, HepG-2, MCF-7, and BJ-1, respectively. Therefore, compound 27 was selected for further investigation. Cell cycle analysis of liver cancer (HepG-2) cells treated with 27 showed cell cycle arrest in the S and G0/G1 phases and strong apoptotic activity, as indicated by Annexin V-FITC staining. Compound 27 was also found to fit in the ATP binding pocket during docking experiments combined with molecular dynamics simulation. Lastly, we conducted a Petra/Osiris/Molinspiration (POM) study on the synthesized compound. The most promising candidates were identified by evaluating primary in silico parameters, which showed considerable differences among individual synthesized compounds. These features can promote future drug candidate design to produce better derivatives in the search for anticancer agents, particularly those with favorable ADME parameters, low toxicity, anticipated bioactivity, and bright futures.

Design, synthesis, and biological evaluation of novel benzo[6,7]indolo[3,4-c]isoquinolines as anticancer agents with topoisomerase I inhibition

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors

Synthesis, Crystal Structure and Evaluation of Cancer Inhibitory Activity of 4-[Indol-3-yl-methylene]-1h-pyrazol-5(4h)-one Derivatives

Synthesis and Biological Evaluation of Novel Pyrazoline Derivatives Containing Indole Skeleton As Anti-Cancer Agents Targeting Topoisomerase II.

Design, Synthesis and Biological Activity of Pyrazolo[3,4-d]pyrimidine Derivatives Containing Indole Moiety

Discovery of Indolo[3,2- c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity

Design, Synthesis And Biological Evaluation Of Of Novel Anticancer Agent Tert-Butyl 1-Phenyl-3,4-Dihydro-1h-Pyrido[3,4-B]Indole-2(9h)-Carboxylate

Design, Synthesis, and Investigation of the Pharmacokinetics and Anticancer Activities of Indenoisoquinoline Derivatives That Stabilize the G-Quadruplex in the MYC Promoter and Inhibit Topoisomerase I

Design, Synthesis and Biological Evaluation of the Novel Antitumor Agent 2-Benzyl-3, 4-Dihydroisoquinolin-1(2h)-one and Its Derivatives

Synthesis, Docking and Biological Evaluation of Isoquinolonic Acid Derivatives

Synthesis, biological evaluation, and in silico studies of indole‐tethered pyrazoline derivatives as anticancer agents targeting topoisomerase IIα

Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,4-oxadiazole incorporated indazole-isoxazole derivatives

Synthesis and biological evaluation of indeno[1, 2-b]indole derivatives as dual topoisomerase Ⅰ & Ⅱ inhibitors: novel multidrug resistant reversal anticancer agents

Synthesis, biological evaluation and molecular docking studies of novel 1-(4,5-dihydro-1H-pyrazol-1-yl)ethanone-containing 1-methylindol derivatives as potential tubulin assembling inhibitors

Design, Synthesis and Biological Evaluation of 9-Aryl-5h-pyrido[4,3-b]indole Derivatives As Potential Tubulin Polymerization Inhibitors.

Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships

Design and Synthesis of Indole Pyrimidine Scaffolds as Potential KSP Inhibitors and Anticancer Agents

Design, Synthesis and Structure-Activity Relationship Study of Novel Naphthoindolizine and Indolizinoquinoline-5,12-dione Derivatives As IDO1 Inhibitors

Click synthesis of novel 6-((1 H -1,2,3-triazol-4-yl)methyl)-6 H -indolo[2,3- b ]quinoxalines for in vitro anticancer evaluation and docking studies

Synthesis, anticancer evaluation and mechanism studies of novel indolequinone derivatives of ursolic acid

Design, synthesis and biological evaluation of dual Topo II/HDAC inhibitors bearing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs.